A5060214751- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Respiratory viral infections research
- Immunotherapy and Immune Responses
- Viral Infections and Outbreaks Research
- Viral Infections and Vectors
- Long-Term Effects of COVID-19
- COVID-19 epidemiological studies
International Centre for Diarrhoeal Disease Research
2022-2025
Abstract COVID-19 vaccines have been effective in preventing severe illness, hospitalization and death, however, the effectiveness diminishes with time. Here, we evaluated longevity of antibodies generated by COIVD-19 risk (re)infection Bangladeshi population. Adults receiving two doses AstraZeneca, Pfizer, Moderna or Sinopharm were enrolled at 2–4 weeks after second dosing followed-up 4-monthly interval for 1 year. Data on COVID-like symptoms, confirmed infection, co-morbidities, receipt...
The adaptive immune response is a crucial component of the protective immunity against SARS-CoV-2, generated after infection or vaccination.We studied antibody titers, neutralizing antibodies and cellular responses to four different COVID-19 vaccines, namely Pfizer-BioNTech, Moderna Spikevax, AstraZeneca Sinopharm vaccines in Bangladeshi population (n = 1780).mRNA (14,655 ± 11.3) Pfizer (13,772 11.5) elicited significantly higher anti-Spike (S) titers compared Adenovector vaccine (2443 12.8)...
The study of cellular immunity to SARS-CoV-2 is crucial for evaluating the course COVID-19 disease and improving vaccine development. We aimed assess phenotypic landscape circulating lymphocytes mononuclear cells in adults children who were seropositive past 6 months. Blood samples (n = 350) collected a cross-sectional Dhaka, Bangladesh (Oct 2020-Feb 2021). Plasma antibody responses determined by an electrochemiluminescence immunoassay while lymphocyte monocyte assessed using flow cytometry...
The purpose of this study was to determine the seropositivity circulating viral pathogens and their association with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seropositivity. In a cross-sectional design, inhabitants (aged 10–60 years) slum surrounding non-slum areas Dhaka Chattogram Metropolitan cities in Bangladesh were enrolled from October 2020 February 2021. Antibodies SARS-CoV-2, influenza B, parainfluenza, syncytial virus (RSV), human HKU1 (HCoV-HKU1), dengue...